Skip to main content
Premium Trial:

Request an Annual Quote

Rheos Medicines, PatientsLikeMe Partner on Immune-Mediated Disease Research

NEW YORK — Autoimmune disease drug developer Rheos Medicines said on Thursday that it has partnered with PatientsLikeMe to support its research into the metabolic drivers of immune-mediated diseases.

Rheos said it will combine de-identified data from PatientsLikeMe's now-ended DigitalMe biomarker discovery program, which collected molecular and other biological data from thousands of participants, with multi-omics data from its own patient samples.

Analyzing these data will bolster its efforts to define patients most likely to respond to different therapies, Rheos said, and identify novel drug targets for immune-mediated diseases such as rheumatoid arthritis and lupus.

The Cambridge, Massachusetts-based companies will also work together to expand Rheos' access to additional patient samples, exploring new ways to engage patients.

Additional terms of the deal were not disclosed. 

"Our strategic collaboration with PatientsLikeMe represents an important opportunity to reach patients while further exploring the metabolic pathways that contribute to factors that promote chronic inflammation," Rheos CEO Barbara Fox said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.